Enterprise League logo

Biotechnology Companies in Europe

Biotechnology companies develop, manufacture, and distribute medical devices, diagnostics, or pharmaceutical products for use in clinical, hospital, and research settings. This page lists companies operating in the Biotechnology sector based on self-reported profile data. The directory currently holds 480 companies in this sector. The largest share of listings is based in London. Related sectors on Enterprise League include Medical Equipment and Services, Life Science, Genetics, Pharmaceutical, Biopharma, Clinical Trials, Nanotechnology.
480 companies
London top city

Europe
Biotechnology
List of Biotechnology companies in Europe

480 companies

Sort by

LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™). Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology and robotics.
Machine learning
Artificial Intelligence
Robotics
Biotechnology
Therapeutics

2012

Materials technology startup unlocking the potential of nanofibers with #halospinning for cultured meat, tissue engineering, wound care, filtration, and more. Our proprietary high-throughput nanofiber production technology HaloSpin™ is the fastest solution-spinning technology. We are especially focused on the production of bio-based nanofibers, but can work with variety of different polymers. Compared to electrospinning, our technology enables over 90% price reduction and is the ideal solution for applications such as tissue engineering, cultured meat, drug discovery, wound care, energy storage, filtration, and more. We are providing nanofiber manufacturing as well as development services for companies to develop the materials for a specific application. We have developed our own edible 100% vegan scaffolds for cultured meat and are continuously developing new products also on our own.
Industrial Machinery and Equipment
Food Processing
Energy Storage
Advanced Materials
Nanotechnology
B2B
Biotechnology

2016

GenePlanet is the leading European provider of preventive genetic tests, specialising in NIPT, cancer screening, and lifestyle DNA tests. With over 15 years of experience in the market, GenePlanet collaborates with over 1000 medical centres, doctors, and insurance companies to provide top-quality tests based on the latest scientific discoveries. The company’s tests are designed to empower individuals to take control of their and their baby’s health, as well as assist doctors with therapeutic procedures. GenePlanet adheres to the highest standards of quality and is constantly striving for new discoveries through its research and development efforts. With a presence in more than 35 countries worldwide and over 100,000 satisfied customers, GenePlanet has been recognised as one of the 1000 fastest-growing companies in the EU by the Financial Times and one of the Top 35 EU Unicorns by the European Commission.
Biotechnology

2008

GQ Bio is pioneering a high-capacity gene therapy vector platform (HCAd) that addresses some of the big challenges in the gene therapy field: Transfer of large and multiple genes with a single vector, highly efficient gene delivery (high transduction efficiency), and large-scale manufacturability. Based on its HCAd vector platform, GQ Bio develops transformative treatments for chronic, prevalent conditions such as osteoarthritis and intervertebral disc degeneration. GQ Bio is headquartered in Hamburg, Germany and has sites at Luckenwalde (greater Berlin area), Germany and Liège, Belgium.
Developer Tools
Biopharma
Healthcare
Biotechnology

2012

Created in 2001, Genoscreen provides genomic services and innovative solutions in genomics. Our offer addresses academic and industrial research teams which need to analyse DNA and explore its properties. The health, agrofood and environmental sectors are our main markets. The company’s portfolio includes: • Services in molecular biology analyses (DNA sequencing, genotyping, detection of gene mutation, metagenomics analysis in complex environment…) • Innovative kits to standardize and facilitate specific analyses (kit for microorganisms strains tracing, kit for identification of microbial community in all kinds of environment…) • Expertise and consultancy services for companies which develop projects in genomics GenoScreen also proposes custom-made trainings to people wishing to learn or improve their level about genomic analyses. GenoScreen collaborates to international research programs on Alzheimer’s disease, epidemiological surveillance of pathogens and biodiversity. Key figures: • 30 employees, doctors, engineers and technicians • 300 customers across the 5 continents • 35% of revenues coming from 30 countries outside France • 30% of revenues dedicated to R&D
Environmental Protection Consulting and Education
Healthcare
Biotechnology

2001

Gentronix is a specialist CRO focused on delivering predictive toxicology products & services to global chemical sectors. Working with companies from early screening through to regulatory safety assessment, we deliver innovative solutions for both genetic toxicology and skin sensitisation. For 20 years, Gentronix Ltd has provided predictive toxicology solutions to global chemical industries; enabling our clients to optimise their development programmes via early identification of genotoxic hazard and assessment of chemical safety. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity products & services, along with assessment of skin sensitisation potential.
Cosmetics
Market Research
Legal Research Services
Biotechnology

1999

GFBiochemicals is a biochemical company that specializes in the research, development, production and business development of bio-based and renewable chemicals. We provide high-quality, bio-based chemicals to businesses across the world. Our focus is green chemistry – a sustainable alternative to traditional oil-based chemistry. Our technology is proprietary and has been developed in-house over many years. GFBiochemicals is headquartered in Paris, France and has subsidiaries in Geleen, the Netherlands and Minneapolis, USA. GFBiochemicals acquired Segetis, in 2016, as part of our growth strategy to integrate further in the downstream value chain of levulinic acid. After years of research and development, we started production of levulinate based biosolvents in 2018, by our Joint Venture Company, NXTLEVVEL Biochem (www.nxtlevvel.com). We have an experienced team of researchers, chemical engineers, and business developers.
Manufacturing
Biotechnology
Life Science

2013

GlowDx is developing the Worlds First True Point-of-Care (POC) Diagnostics Platform, aimed at tackling Infectious Disease in Emerging Economies. Our first test detects mosquito-bourne infections (Dengue Fever, Chikungunya & Zika Virus), while our AI utilizes machine learning to model & predict future outbreaks.
Health Centers
Medical Equipment and Services
Health and Medical Products
Healthcare
Biotechnology

2015

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.
Biotechnology

2020

Gradientech is a Swedish biotech and diagnostics company dedicated to support the modern microbiology lab with state-of-the-art solutions to facilitate the workflow with time-critical samples. Our product QuickMIC® is an ultra-rapid system for antibiotic susceptibility testing (AST) of positive blood culture samples from sepsis patients. QuickMIC® is a scalable system with each instrument module analysing one sample against multiple antibiotics, well-suited for small and larger clinical laboratories. MIC values are reported in as short as 2 hours, making it more rapid than any other diagnostic system for phenotypic AST on the market. Gradientech’s technology combines microfluidics with live cell imaging to study cell responses in a linear concentration gradient. Our technology is a perfect match for many biological applications. Gradientech holds an ISO13485 certification.
Medical Equipment and Services
Medical
Healthcare
Biotechnology
Life Science

2009

Imagen Therapeutics is a biotech company based in the UK, with an ongoing commitment to improving the outcomes of cancer patients by accelerating drug discovery and the development of new cancer therapies. Our main activities include offering personalised clinical diagnostic services to cancer patients, offering contract research services, and developing a world-leading well-characterised Biobank.
Biotechnology
Life Science

2007

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).
Pharmaceutical
Healthcare
Biotechnology

2014

Our Vision: Our intelligent sensing platforms integrated on all plasma and RF processing equipment to enable atomic-scale engineering for the advancement of nano-technology. Our Mission: Creating intelligent sensing platforms for advanced plasma and RF manufacturing processes, to improve process performance and reduce product scrap. Our Purpose: Our company exists because we believe in the science of measurement. We believe that accurate process measurement is critical for the future of nano-scale manufacture, where process stability and repeatability are paramount to delivering the technology of the future. We measure parameters and processes under some of the most extreme environments encountered on earth. We measure things often considered impossible. #MeasuringTheImpossible. Our value proposition is that we provide you with an independent diagnosis of your process health, using intelligent, network-enabled sensing platforms, in conjunction with our vast experience in RF and plasma systems, to help you solve the most complex processing issues.
Manufacturing
Healthcare
Bioinformatics
Biotechnology

2004

Impulse Dynamics is dedicated to improving the lives of people with heart failure and is the developer of the innovative Optimizer®CCM® therapy delivery system. CCM® therapy is a breakthrough heart failure treatment that is proven to improve quality of life for heart failure patients. CCM® therapy is specifically designed to improve contraction of the heart in an effort to deliver more oxygen-rich blood to the body. CCM® therapy is a safe and effective minimally invasive treatment option for millions of heart failure patients who otherwise have few or no effective options available to them Optimizer was granted Breakthrough Device designation by the FDA and is the first and only FDA-approved device in the U.S. or elsewhere for the delivery of CCM® therapy. For important safety info visit: http://bit.ly/303mFRN
Medical Equipment and Services
Health and Medical Products
Medical
Biotechnology
Hospital

1998

At LenioBio, we develop efficient, robust and sustainable technologies to disrupt the way medicines and food are produced for those in need, wherever they are. Unconstrained by the limitations of cells, we combine our proprietary protein technology with machine learning to significantly accelerate innovation cycles in life science industry.
Biotechnology

2016

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families. The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.
Biotechnology
Therapeutics
Life Science

2020

GAIAGO is an Agtech company based in the region of St Malo, France. Only healthy Soils allow abundant and quality food production. We produce a new generation of Soil improvements tools, effective for all agricultures. We contribute to the farmer’s mission: cultivate and transmit a healthy and fertile Soil
Farming Services
Biotechnology
AgTech
Agriculture

2014

GoodGut is a biotechnology company focused on researching and developing analysis systems and therapeutic products to improve the diagnosis and treatment of digestive diseases based on intestinal microbiota. We aim to provide technological tools that will help to obtain a faster, more reliable and lower cost medical diagnosis than existing methods, alongside therapies to improve the quality of life of patients with compromised digestive health. The company was created in 2014 as a spin-off of the University of Girona (UdG) and the Institute of Biomedical Research of Girona Dr. Josep Trueta (IdIBGi). Our facilities can be found in the Scientific and Technologic Park of the UdG, an innovation hub housing over 140 companies, research groups and institutions.
Health Centers
Health and Medical Products
Healthcare
Biotechnology

2014

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.
Medical Equipment and Services
Health and Medical Products
Medical
Biotechnology
Life Science

2016

The forest is a renewable resource. Lignin is a by-product from the pulping industry. Globally 80 million tonnes is processed in the pulping industry, making it the largest natural by-product on earth. Today, 99% of the produced lignin is burnt for its energy value. We, at Lignin Industries, convert lignin so it can be blended with virgin and recycled thermoplastics creating new types of bioplastics. For every 1 kg of fossil based plastics replaced by RENOL® we decrease CO₂ up to 6 kgs released into the atmosphere. We can provide the plastic industry with large amounts of granulates for several market segments ranging from packaging, agricultural films and injection moulding pieces. Lignin Industries is one of the few selected companies among 232 proposals to be supported by the European Union Innovation Fund that will co-fund Lignin Industries by financing the expansion of the first-of-its-kind large-scale production site, located in Sweden. The funding was given under the call “Innovation Fund” with the aim to support projects demonstrating highly innovative technologies and products that have a significant potential to reduce greenhouse emissions.
Manufacturing
Biotechnology

2018

LUMICKS is the leading supplier of dynamic single-molecule and cell avidity analysis instruments. Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells. Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail. Our goal is to advance science and improve human health, by providing tools that unlock the measurement of forces and interactions in biology. For the first time ever, our unapparelled solutions can assist research by directly linking structural and ‘omics analysis to functional outcomes at both a molecular and a cellular level. This is achieved by applying and measuring forces around biological interactions, enabling the detailed real-time analysis of underlying biological mechanisms.
Medical Equipment and Services
Health and Medical Products
Biotechnology
Life Science

2014

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.
Health Centers
Medical Equipment and Services
Health and Medical Products
Healthcare
Biotechnology
Life Science

2014

Mcule operates chemical marketplaces for drug discovery complemented with services based around small-molecule compound sourcing. While the traditional Mcule database aggregates a wide variety of supplier catalogs, Mcule ULTIMATE database contains novel, synthetically accessible compounds. Mcule SynthAgora is a custom synthesis marketplace that enables our clients to receive offers conveniently for structures that are not available in any catalogs in the world.
Cloud Services
E-Commerce Development
IT Consulting Services
Healthcare
Biotechnology
Database

2011

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Its DROPZYLLA™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. Combined with our microfluidic high throughput single cell-based functional screening system this leads to entirely new possibilities in immune repertoire analysis and antibody discovery. The business strategy of Memo Therapeutics is the discovery of therapeutic antibody candidates and target discovery for antibody and vaccine development. DROPZYLLA™ is deployed in proprietary antibody discovery programs and is made available in collaborations e.g. for screening of CAR-T; TCR-T or bi-specific antibodies.
Biotechnology
Collaboration

2012

Methinks vision is to provide universal and timely diagnosis for life-saving treatments worldwide. Our first focus is on stroke, the second cause of death and a major cause of disability in the world. Our product is an artificial intelligence medical imaging software capable of performing stroke triage and unlock stroke treatments potential from non-contrast CTs. Methinks is a VC backed digital health start-up that recently won the prestigious EIC Accelerator of the European Commission and has obtained two gold medals in the RSNA Kaggle competitions. The recent funding of the company will allow us to grow rapidly and we are looking for exceptional and passionate individuals to help us face these challenges and build together a unique company.
IT Services
Medical Equipment and Services
Artificial Intelligence
IT Consulting Services
Medical
Biotechnology
Life Science

2016

Metrion Biosciences is a UK-based Contract Research Organization specialising in high quality ion channel screening and drug development expertise. We aim to provide our customers with access to a range of in vitro screening services that includes cardiac safety (hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, our management team have amassed over 80 years of experience in ion channel drug discovery and our clients can access this high level of expertise as part of our dedicated service.
Market Research
Medical
Collaborative Consumption
Healthcare
Biotechnology
Life Science
Neuroscience

2015

Micrima was founded in 2006 to develop and commercialise microwave radar breast imaging technology initially pioneered at the University of Bristol in the UK. The company's MARIA system is currently in clinical trials to collect valuable data for our machine learning algorithm's. The latest step in the journey to Breast Screening will be launched in 2022. This new system will provide density information and improved ergonomics for patient and operator. Contact us to arrange to see this system or to find out more.
Medical Equipment and Services
Health and Medical Products
Medical
Healthcare
Biotechnology

2006

MicrobesNG is an innovative microbial genome sequencing service. We provide value driven whole genome and metagenome sequencing and bioinformatics analysis to our global customer base for microbial applications (including bacterial, fungal and viral samples.) Our journey so far has been amazing! Founded in 2014 within the University of Birmingham, with support of a BBSRC grant, we established our business and began to thrive. The next chapter in our evolution came in August 2019 when we “spun out” of the University after 5 years of successful operation. Since then it’s been onwards and upwards. We are on a mission to deliver high value, quality sequencing data within academia and the public and private sectors. We consistently strive to ensure that our service offerings and capabilities match those required by our customers. Providing a positive customer experience is at our core and we place our fantastic customers at the heart of everything we do. We enjoy a high percentage of repeat business demonstrating that we consistently deliver on our promises to our customers. Our highly qualified and experienced teams excel at delivering quality sequencing data for both “high volume” and “single sample” projects. Our service experience has made us specialists in coordinating projects involving multiple collaborators across different continents while incorporating the ability to deliver a personalised service. Our teams are always available to provide support and guidance for those customers that are new to microbial genome sequencing. MicrobesNG really is a sequencing service for all users!
Biotechnology

2019

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets. Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
Healthcare
Biotechnology
Therapeutics

2016

We brings precise microencapsulation at industrial scale: Microcaps developed a novel technology that enables the scalable production of precise microcapsules and microparticles based on microfluidics. With this invention, microcaps is able to increase the controlled production by a factor of 1000 compared to state-of-the-art technologies. Our goal is to provide an upscalable, fully-automated encapsulation micro-factory, that enables size control, precise dosing and increased stability of the microcapsules and microparticles.
Chemicals
Manufacturing
IT Services
Computer Hardware
IT Consulting Services
Medical
Chemical Engineering

2019

MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.
AR and VR Development
Healthcare
Biotechnology
Therapeutics
Neuroscience

2012

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million
Medical
Pharmaceutical
Healthcare
Biotechnology
Genetics

2011

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.
Healthcare
Biotechnology
Therapeutics
Life Science

2011

At Mycorena, we are on a mission to significantly change how we produce and consume food. We believe in the power of fungi and want to pave the way for a sustainability revolution by offering the industry scalable, high-quality products. Through innovative technology, we develop sustainable mycelium-based solutions for the food industry. Our flagship product Promyc is a proprietary vegan mycoprotein with superior nutritional value in protein, fibre, vitamins, and minerals. With a neutral taste and a satisfying fibrous texture, Promyc offers the most demanded qualities in the alternative protein segment. What originated as a research project has grown into one of the fastest-growing companies in the industry. Since our founding in 2017, we have scaled from a small lab to Scandinavia’s largest demo production facility for mycoprotein. We are expanding further as we prepare to commence commercial production in our new Promyc Production Plant, the first of its kind in Scandinavia. Our vision is to be world-leading in fungi-based technology and drive the change in the food system for a sustainable tomorrow. The future of food is now.
Manufacturing
Food Processing
Food Manufacturing
Food Vendors
Biotechnology

2017

#Nanolive: Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics. Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.
3D Technology
Biotechnology

2013

Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientist in research and drug development. Founded in 2004 on the breakthrough innovations by Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016. Navinci has also launched several daughter companies such as Olink Proteomics (noted Nasdaq NY: OLK) for high-throughput protein analysis in blood, Q-linea (noted on Nasdaq) focusing on counteracting antibiotic resistance in sepsis, and Halogenomics (acquired by Agilent) in target selection for next generation sequencing. Moreover, the company has outlicensed IP rights to several leading international life science companies. Navinci holds a broad and growing patent portfolio utilizing oligonucleotide-conjugated antibodies for detection of proteins and their interactions. From our base in Uppsala, Sweden, Navinci contributes to improve human health by serving scientist with sharp and tailored tools to study proteins and their interactions in order to understand human biology and develop better drugs.
Health Centers
Health and Medical Products
Healthcare
Biotechnology

2004

NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.
Legal Translation Services
Biotechnology
Therapeutics

2017

We are a biotechnology-based company focused on the exploitation of marine biodiversity applied to human needs. The company was born with the objective of developing and bringing innovative solutions to the world for problems in different markets, using one of the richest and most diverse groups of organisms on the planet: microalgae. Research and development are the soul and engine of our company and therefore we constantly collaborate in research and development projects with the most recognized research centers and universities in the world. The founders of NEPTUNUS BIOTECH have more than 25 years of experience giving sustainable and innovative solutions to the agricultural industry. In addition to having a world-class and personal scientific council with more than 30 years working with microalgae, plants and other photosynthetic organisms. The technological platform of NEPTUNUS BIOTECH provides solutions to three different markets: agricultural, food and personal care.
Biotechnology

2019

Netabolics, part of Microsoft for Startups Founders Hub, develops an insilico target selection platform that integrates the predictive power of artificial intelligence and machine learning (AI/ML) with the explainable nature of biosimulation based on first principles of physics and biology.
Artificial Intelligence
Biotechnology
Life Science

2020

Nova provides its jinkō clinical trials simulation platform to biotech and pharma companies, academic research centers and not-for-profit organizations. Jinkō® unlocks the potential of modeling & simulation to de-risk and accelerate the R&D of new therapies for the benefit of patients: identify best responders, optimise the drug's regimen, generate synthetic control arms, explore research outcomes that might not be feasible with conventional trials. Predict trial outcomes before advancing to real-world clinical trials and ultimately design studies that are more likely to succeed with Jinkō®.
IT Services
Artificial Intelligence
IT Consulting Services
Software
Medical
CRM
Healthcare

2010

Nuclera is making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day. Biological research and drug discovery projects begin with and rely on proteins. However, using traditional methods to obtain proteins of interest can take up to 6 months and often include many trials and failures. What if there was an easier way? At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.
Industrial Engineering
Pharmaceutical
Biotechnology
Life Science

2013

The North West Biotech Initiative (NWBI) provides a platform that encourages knowledge sharing and dialogue between young students, local and international businesses and industry experts. We promote the development of early stage researchers in the STEM fields by providing an inclusive space for fostering relationships between academia and the growing local biotech sector. This provides students the power of choice; to choose a career path based on interest and passion and not due to a lack of skills or opportunities. Thus, students will be prepared to apply in-demand professional skills in any arena and sector they choose to pursue in life beyond their academic institutions.
Biotechnology

2014

See protein, DNA and RNA molecules that make life work, in nanoparticles, viruses, bacteria, cells and tissue. We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the world's first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before. We can’t wait to see and hear about what new questions you will ask!
Software
Nanotechnology
Biotechnology
Life Science

2016

Our mission is to help life sciences companies accelerate drug development for improved patient outcomes, and we do this by championing the power of data. Our main product DISQOVER is an optimized search or knowledge platform which draws on semantic technology and an ontology-based knowledge graph to find links between data across databases (internal data, public data and third party data) faster and more efficiently. The platform has been developed for the pharmaceutical and biotech industries. There are thousands of health research databases, clinical trials, literature reviews, patient studies, etc. available. Before setting up a new study, scientists first need to check what kind of research has already been done – both internally and externally – on, for instance, growth hormone applications for a particular disease. In many companies, even internal information resides in hundreds of different databases, each with their own interface and search logic. As a consequence, just finding this kind of background information is a very time-consuming process. This is where DISQOVER comes in. One of the assets is that we use semantic technology to find logical but often hidden connections between internal and external data, allowing you to easily combine information from a multitude of different sources. As such, pharma and biotech companies can save valuable time and money that they can now invest in developing new medicines or treatments. Customers include: AstraZeneca, AmGen, Medidata, Prinses Máxima Institute, Aelin Therapeutics and more. DISQOVER is used amongst others by scientific researchers, bioinformaticians, and data scientists. Try DISQOVER: our community edition is always up-to-date and accessible via www.ontoforce.com (choose “try now” top right corner)
IT Services
IT Consulting Services
Software
Pharmaceutical
Data Integration
Data Visualization
Biotechnology

2011

With so much potential for biotech to make the world a better place to live, we knew we needed to make the lab a better place to work. We’re a team of scientists and designers who have meticulously studied the in-lab experience, getting a detailed understanding of workflows and identifying common pain points that routinely cost scientists time and money. Our BioHotel labs are designed with biotech startups in mind: - Short term, flexible leases - Central London locations in key life sciences clusters - BSL2 lab spaces that can be tailored to your workflow - Specialist services including cryogenic freezer storage, glassware washing and sterilisation and a lab coat laundry - Access to bookable specialist labs and equipment - All-inclusive clinical, chemical and general waste services - Discounts and free delivery from our store
Biotechnology

2018

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System™ (EDS®) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. In March and June 2022, we announced positive top line results from our two Phase 3b clinical trials (ReOpen1 and ReOpen2) of XHANCE for a follow-on indication for the treatment of chronic sinusitis. In February 2023, we submitted a prior approval efficacy supplement (sNDA) to support the approval of a new indication for XHANCE for the treatment of chronic rhinosinusitis. If the sNDA is approved, XHANCE has the potential to be the first drug therapy approved by the FDA for the treatment of chronic sinusitis. As of February 20, 2023, we had a total of 141 full-time employees all of whom are in the United States, and no part-time employees. Culture is a critical element in the management of our organization. Our colleagues are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.
Manufacturing
Medical Equipment and Services
Health and Medical Products
Pharmaceutical
Biotechnology

2010

Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments. By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.
Manufacturing
Industrial Machinery and Equipment
Industrial Automation
Biotechnology
Therapeutics

2015

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.
Medical
Biopharma
Healthcare
Biotechnology
Therapeutics
Genetics

2000

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.
Medical Equipment and Services
Health and Medical Products
Medical
Pharmaceutical
Biotechnology

2012

Osivax’ mission is to develop “universal” vaccines against highly-mutating viruses. Leveraging its unique oligoDOM® technology platform, OSIVAX is developing a universal vaccine for both current and future influenza infections. The Company’s universal flu vaccine candidate, OVX836 is in Phase 2a clinical development. OSIVAX is leveraging the same platform technology for the development of a universal vaccine against all existing and emerging coronavirus infections. OSIVAX is focused on providing proof-of-concept in influenza and coronavirus, and to applying its oligoDOM® platform broadly in other infectious and immune system-associated diseases.
Clinical Trials
Healthcare
Biotechnology

2017

List of Biotechnology companies in Europe

Company Name

Location

Category

Employees

Website

London, United Kingdom (UK)

Information Technology
+2
Information Technology, Science and Engineering, Health and Medical

50-100

https://labgeni.us/

Tallinn, Estonia

Manufacturing and Industry
+4
Manufacturing and Industry, Food and Beverages, Energy, Science and Engineering, Other

10-20

https://www.gelatex.com/

Ljubljana, Slovenia

Science and Engineering
Science and Engineering

150-200

https://geneplanet.com/eu

Hamburg, Germany

Information Technology
+2
Information Technology, Health and Medical, Science and Engineering

20-30

https://www.gq-biotx.com/home-2.html

Lille, France

Environment
+2
Environment, Health and Medical, Science and Engineering

30-50

https://www.genoscreen.fr/fr/

Manchester, United Kingdom (UK)

Beauty and Personal Care
+3
Beauty and Personal Care, Sales and Marketing, Legal, Science and Engineering

50-100

https://gentronix.co.uk/

Milan, Italy

Manufacturing and Industry
+1
Manufacturing and Industry, Science and Engineering

30-50

http://www.gfbiochemicals.com/company/

Galway, Ireland

Health and Medical
+1
Health and Medical, Science and Engineering

20-30

https://www.glowdx.com/

Schlieren, Switzerland

Science and Engineering
Science and Engineering

20-30

https://glycoera.com/

Uppsala, Sweden

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://gradientech.se/

Manchester, United Kingdom (UK)

Science and Engineering
Science and Engineering

20-30

https://www.imagentherapeutics.com/

Schlieren, Switzerland

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.immunostherapeutics.com/

Dublin, Ireland

Manufacturing and Industry
+2
Manufacturing and Industry, Health and Medical, Science and Engineering

10-20

https://www.impedans.com/

Stuttgart, Germany

Health and Medical
+1
Health and Medical, Science and Engineering

150-200

https://impulse-dynamics.com/

Düsseldorf, Germany

Science and Engineering
Science and Engineering

30-50

https://www.leniobio.com/

Amsterdam, The Netherlands

Science and Engineering
+1
Science and Engineering, Health and Medical

50-100

https://leydenlabs.com/

Saint-Malo, France

Agriculture and Livestock
+1
Agriculture and Livestock, Science and Engineering

30-50

https://www.gaiago.eu/

Girona, Spain

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://goodgut.eu/

Utrecht, The Netherlands

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.lavatherapeutics.com/

Uppsala, Sweden

Manufacturing and Industry
+1
Manufacturing and Industry, Science and Engineering

20-30

https://www.lignin.se/

Amsterdam, The Netherlands

Health and Medical
+1
Health and Medical, Science and Engineering

200-500

https://lumicks.com/

Lausanne, Switzerland

Health and Medical
+1
Health and Medical, Science and Engineering

100-150

https://lunaphore.com/

Budapest, Hungary

Information Technology
+4
Information Technology, Business Services, Health and Medical, Science and Engineering, Data and Analytics

20-30

https://mcule.com/

Schlieren, Switzerland

Science and Engineering
+1
Science and Engineering, Other

20-30

https://memo-therapeutics.com/home.html

Barcelona, Spain

Information Technology
+3
Information Technology, Health and Medical, Business Services, Science and Engineering

10-20

https://www.methinks.ai/

Cambridge, United Kingdom (UK)

Sales and Marketing
+3
Sales and Marketing, Health and Medical, Other, Science and Engineering

30-50

https://www.metrionbiosciences.com/

Bristol, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

10-20

https://www.micrima.com/

Birmingham, United Kingdom (UK)

Science and Engineering
Science and Engineering

10-20

https://microbesng.com/

Cambridge, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://microbiotica.com/

Schlieren, Switzerland

Manufacturing and Industry
+5
Manufacturing and Industry, Information Technology, Electronics, Business Services, Health and Medical, Science and Engineering

20-30

https://microcaps.ch/

Lausanne, Switzerland

Information Technology
+2
Information Technology, Health and Medical, Science and Engineering

150-200

https://mindmaze.com/

Barcelona, Spain

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://www.minoryx.com/

Cambridge, United Kingdom (UK)

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

http://missiontherapeutics.com/

Gothenburg, Sweden

Manufacturing and Industry
+2
Manufacturing and Industry, Food and Beverages, Science and Engineering

50-100

https://mycorena.com/

Ecublens, Switzerland

Design Services
+1
Design Services, Science and Engineering

50-100

https://www.nanolive.ch/

Uppsala, Sweden

Health and Medical
+1
Health and Medical, Science and Engineering

20-30

https://navinci.se/

Cambridge, United Kingdom (UK)

Legal
+2
Legal, Science and Engineering, Health and Medical

10-20

https://www.neophore.com/

Manchester, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://neptunusbiotech.com/

Rome, Italy

Information Technology
+1
Information Technology, Science and Engineering

2-10

https://netabolics.ai/

Lyon, France

Information Technology
+3
Information Technology, Business Services, Health and Medical, Science and Engineering

50-100

https://www.novadiscovery.com/

Cambridge, United Kingdom (UK)

Manufacturing and Industry
+2
Manufacturing and Industry, Health and Medical, Science and Engineering

100-150

https://www.nuclera.com/?utm_source=linkedin&utm_medium=social&utm_campaign=company%2Bpage%2Bweb%2Blink

Manchester, United Kingdom (UK)

Science and Engineering
Science and Engineering

2-10

https://www.nwbiotech.co.uk/

Oxford, United Kingdom (UK)

Information Technology
+1
Information Technology, Science and Engineering

100-150

https://oni.bio/

Ghent, Belgium

Information Technology
+3
Information Technology, Business Services, Health and Medical, Science and Engineering

30-50

https://www.ontoforce.com/

London, United Kingdom (UK)

Science and Engineering
Science and Engineering

10-20

https://www.opencell.bio/

Oslo, Norway

Manufacturing and Industry
+2
Manufacturing and Industry, Health and Medical, Science and Engineering

150-200

https://www.optinose.com/

London, United Kingdom (UK)

Manufacturing and Industry
+2
Manufacturing and Industry, Science and Engineering, Health and Medical

50-100

https://oribiotech.com/

Barcelona, Spain

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://www.oryzon.com/en

Nantes, France

Health and Medical
+1
Health and Medical, Science and Engineering

50-100

https://www.ose-immuno.com/

Lyon, France

Health and Medical
+1
Health and Medical, Science and Engineering

30-50

https://osivax.com/

150/480 results

Frequently asked questions

Updated 23 October 2026

What is Enterprise League?

Enterprise League is a free business directory that helps buyers find the right company by sector and country. Every company has a profile showing what it does, what it offers and how to get in touch.

Is it free to list my company?

Yes, and it stays free: no card, no paid tier. Your profile appears in search results and category pages, can show up to 20 products and services, and lets buyers message you or ask for a quote.

How does verification work, and what does it cost?

Verifying your company is free. Confirm a code we email to an address at your company’s website, or send a company registration document for our team to check, and the verified badge appears on your profile. To show the badge in the directory and search results as well, take out a subscription: the first 14 days are free, and the price is on our pricing page.

Where does the company information come from?

Most profiles are built from public sources, such as official company registers. Claim your company’s profile to correct its details and add your own.

How do I claim or correct my company’s profile?

Open your company’s profile and choose Claim Profile. If you use an email address at your company’s website, a 6-digit code makes the profile yours at once; otherwise our team reviews your request, usually within a few days. Spotted a mistake on a company that isn’t yours? Tell us through our contact page.